Israel may be starting to show 'herd effects' of Pfizer-BioNTech COVID-19 vaccine, expert suggests
Israel has vaccinated at least 25 percent of its population against the coronavirus so far, which leads the world and makes it "the country to watch for herd effects from" the Pfizer-BioNTech COVID-19 vaccine, says infectious disease expert David Fishman. Recently, the case rate in Israel appears to have declined sharply, and while there could be a few reasons for that, it's possible the vaccination effort is beginning to play a role.
One study from Clalit that was published last week reports that 14 days after receiving the first Pfizer-BioNTech shot, infection rates among 200,000 Israelis older than 60 fell 33 percent among those vaccinated compared to 200,000 from the same demographic who hadn't received a jab.
At first glance, Fisman writes, that might seem disappointing since clinical trials suggested the vaccine was more than 90 percent effective. But he actually believes the 33 percent figure is "auspicious." Because vaccinated and non-vaccinated people are mingling, there could be "herd effects of immunization." In other words, when inoculated people interact with people who haven't had their shot, the latter individual may still be protected because the other person is. On a larger scale, that would drive down the number of infections among non-vaccinated people, thus shrinking the gap between the two groups' infection rates.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
More data needs to come in, and Fisman thinks "we'll know more" this week, but he's cautiously optimistic about how things are going.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
What happens to a Democratic Party without Nancy Pelosi?TODAY'S BIG QUESTION The storied former speaker of the House is set to retire, leaving congressional Democrats a complicated legacy and an uncertain future
-
The plant-based portfolio diet focuses on heart healthThe Explainer Its guidelines are flexible and vegan-friendly
-
Gregory Bovino: the officer leading Border Patrol’s aggressive tacticsIn the Spotlight He has been referred to as the Border Patrol’s ‘commander-at-large’
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
RFK Jr. vaccine panel advises restricting MMRV shotSpeed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Texas declares end to measles outbreakSpeed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agencySpeed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year highSpeed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, changeSpeed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panelspeed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kidsSpeed Read The Health Secretary announced a policy change without informing CDC officials
